Content about Pharmaceutical sciences

December 9, 2013

Pharmacy Quality Solutions on Monday announced that it will collaborate with Cardinal Health to help 600 community pharmacies track their performance on Medicare Part D Star measures.

SPRINGFIELD, Va. — Pharmacy Quality Solutions on Monday announced that it will collaborate with Cardinal Health to help 600 community pharmacies track their performance on Medicare Part D Star measures. 

December 6, 2013

The Food and Drug Administration has approved a treatment for a sexual deformity that affects men.

SILVER SPRING, Md. — The Food and Drug Administration has approved a treatment for a sexual deformity that affects men.

December 6, 2013

Health Mart, a community franchise of more than 3,000 independently owned pharmacies across all 50 states, announced that it will offer its member pharmacies access to Pharmacy Quality Solutions' EQuIPP.

SAN FRANCISCO — Health Mart, a community franchise of more than 3,000 independently owned pharmacies across all 50 states, on Friday announced that it will offer its member pharmacies access to Pharmacy Quality Solutions' EQuIPP, an online information management platform that makes pharmacy performance data available to health plans and community pharmacy organizations. 

December 6, 2013

McKesson's Health Mart pharmacy franchisees recently gained access to a tool that has the potential of giving community pharmacy a leg up on the competition in the coming years. EQuIPP, from Pharmacy Quality Solutions, does just that — equips independents with individual store data that marks the performance of their pharmacy vs. a national benchmark.

It's putting the pestle where the mortar is — retail pharmacy has the patient touchpoints and data-tracking wherewithal to make a material impact on patient outcomes. Important, because that's what the new year will bring — more and more healthcare payers looking to improve their own patient outcomes. And what better way to do it than to partner with outperforming pharmacies?

McKesson's Health Mart pharmacy franchisees recently gained access to a tool that has the potential of giving community pharmacy a leg up on the competition in the coming years. EQuIPP, from Pharmacy Quality Solutions, does just that — equips independents with individual store data that marks the performance of their pharmacy vs. a national benchmark. 

December 6, 2013

A study conducted among rural patients at Thrifty White Pharmacy locations in the Midwest and published in the November/December issue of the Journal of the American Pharmacists Association found that patients who received appointment-based medication synchronization were up to six times more likely to adhere to their therapies than those who didn't receive them.

Over the years, study after study has shown that pharmacists can play a crucial role in ensuring that patients take their drugs when they're supposed to and as instructed. And poor medication adherence is no small issue, as studies have shown it costs the country nearly $300 billion per year, in addition to contributing to poor health outcomes. It's been said that improvements in medication adherence can be the equivalent of a blockbuster drug, and according to the National Coalition on Health Care, self-management of chronic diseases could save $10 for every $1 spent.

A study conducted among rural patients at Thrifty White Pharmacy locations in the Midwest and published in the November/December issue of the Journal of the American Pharmacists Association found that patients who received appointment-based medication synchronization were up to six times more likely to adhere to their therapies than those who didn't receive them.

December 6, 2013

Teva Pharmaceutical Industries' U.S. subsidiary has launched a generic drug for treating warts and skin lesions, the company said.

NORTH WALES, Pa. — Teva Pharmaceutical Industries' U.S. subsidiary has launched a generic drug for treating warts and skin lesions, the company said.

Teva Pharmaceuticals announced the launch and availability of imiquimod cream, a generic version of Medicis Pharmaceutical Corp.'s Aldara.

The drug is used to treat external genital and rectal warts, certain types of actinic keratosis and basal cell carcinoma. Various versions of the drug had sales of about $244 million in 2011, according to IMS Health.

 

December 5, 2013

Compounding pharmacies that produce sterile drugs can register as outsourcing facilities and may be exempt from certain Food and Drug Administration approval requirements, according to a document published on the FDA's website.

NEW YORK — Compounding pharmacies that produce sterile drugs can register as outsourcing facilities and may be exempt from certain Food and Drug Administration approval requirements, according to a document published on the FDA's website.

December 4, 2013

Cardinal Health Foundation recently awarded more than $350,000 in grant funding to 29 nonprofit organizations that are dedicated to the fight against prescription drug abuse, the organization announced Wednesday.

DUBLIN, Ohio — Cardinal Health Foundation recently awarded more than $350,000 in grant funding to 29 nonprofit organizations that are dedicated to the fight against prescription drug abuse, the organization announced Wednesday.

Grant recipients were selected from key communities where either a high concentration of Cardinal Health employees live and work, and/or where the community is particularly focused on addressing prescription drug misuse/abuse. Recipients have been awarded funding in amounts ranging from $5,000 to $15,000.

December 4, 2013

Mail-order pharmacies frequently charge Medicare prescription drug plans more than community pharmacies do for filling prescriptions, a new analysis by the U.S. Centers for Medicare and Medicaid Services has concluded.

ALEXANDRIA, Va. — Mail-order pharmacies frequently charge Medicare prescription drug plans more — as much as 83% — than community pharmacies do for filling prescriptions, a new analysis by the U.S. Centers for Medicare and Medicaid Services has concluded.

CMS examined claims from March 2012 and found 21 drug plans that routinely paid more for prescriptions filled through the mail compared to a community pharmacy.

December 4, 2013

The Food and Drug Administration has approved a new topical drug for treating scars made by Oculus Innovative Sciences, the drug maker said Wednesday.

PETALUMA, Calif. — The Food and Drug Administration has approved a new topical drug for treating scars made by Oculus Innovative Sciences, the drug maker said Wednesday.

The FDA has approved Microcyn scar-management hydrogel, used to treat scars resulting from burns, surgery and trauma wounds. Oculus and a partnering company, Quinnova Pharmaceuticals, intend to start selling the drug in the first half of next year.

December 4, 2013

Walgreens on Wednesday reported November sales of $6.1 billion, an increase of 4.1% for the same month in fiscal 2013.

DEERFIELD, Ill. — Walgreens on Wednesday reported November sales of $6.1 billion, an increase of 4.1% for the same month in fiscal 2013.

Total front-end sales increased 3.2%, while comparable store front-end sales increased 1.9%. Customer traffic in comparable stores increased 0.8% and basket size increased 1.1%.

The company said that a meaningful increase versus prior quarters in promotional investment contributed to the improvement in traffic and comparable store front-end sales for November and throughout the quarter.

December 3, 2013

Cardinal Health recently enhanced its Reimbursement Consulting Services offering, which helps retail pharmacies ensure the accuracy of third-party reimbursement by identifying reimbursement errors and recommending strategies for correcting them.

DUBLIN, Ohio — Cardinal Health recently enhanced its Reimbursement Consulting Services offering, which helps retail pharmacies ensure the accuracy of third-party reimbursement by identifying reimbursement errors and recommending strategies for correcting them, the wholesaler announced Tuesday.

According to the NCPA Digest, sponsored by Cardinal Health, independent pharmacies derive 92% of their revenue from prescription reimbursements. However, a number of factors can impact a retail pharmacy’s ability to ensure they receive the reimbursement they’re owed.

December 3, 2013

The Food and Drug Administration has given tentative approval to a generic drug for treating community-acquired pneumonia, agency records showed.

SILVER SPRING, Md. — The Food and Drug Administration has given tentative approval to a generic drug for treating community-acquired pneumonia, agency records showed.

According to the FDA's website, the agency granted the preliminary authorization for Roxane Labs' linezolid oral suspension in the 100-mg-per-5-mL strength.

December 3, 2013

Forest Labs is spending at least $240 million to buy rights to a psychiatric drug made by Merck, the New York-based drug maker said.

NEW YORK — Forest Labs is spending at least $240 million to buy rights to a psychiatric drug made by Merck, the New York-based drug maker said.

Forest said it would buy the U.S. rights for Merck's Saphris (asenapine), a tablet dissolved under the tongue for the treatment of schizophrenia and manic episodes in patients with bipolar disorder. Forest will pay Merck $240 million upfront, as well as milestone payments based on sales, while Merck will supply the drug. Forest will market the drug and conduct clinical studies.

December 3, 2013

Takeda Pharmaceutical Co., the largest drug maker in Japan, has hired the head of GlaxoSmithKline's vaccines division as its COO, Takeda said.

OSAKA, Japan — Takeda Pharmaceutical Co., the largest drug maker in Japan, has hired the head of GlaxoSmithKline's vaccines division as its COO, Takeda said.

Christophe Weber was elected at the drug maker's board of directors meeting to become COO and candidate as the next CEO. Current president and CEO Yasuchika Hasegawa is expected to be named chairman and CEO.

Weber is currently president and general manager of GSK Vaccines, CEO of GSK Biologicals in Belgium and a member of GSK's global corporate executive team.

December 3, 2013

Impax Labs has settled a patent-infringement suit filed by Purdue Pharma concerning the opioid painkiller OxyContin, Impax said Tuesday.

HAYWARD, Calif. — Impax Labs has settled a patent-infringement suit filed by Purdue Pharma concerning the opioid painkiller OxyContin, Impax said Tuesday.

December 3, 2013

McKesson will be introducing hospital and health systems pharmacy leaders to new ideas and emerging solutions for their top issues at the American Society of Health-System Pharmacists Midyear Clinical Meeting 2013, which runs from Dec. 8 to 12.

SAN FRANCISCO — McKesson will be introducing hospital and health systems pharmacy leaders to new ideas and emerging solutions for their top issues at the American Society of Health-System Pharmacists Midyear Clinical Meeting 2013, which runs from Dec. 8 to 12. Organized under the theme “Learn, Network, Solve,” McKesson booth #849 will host solution demonstrations and live interviews, and pharmacy consulting experts will be on hand for one-on-one discussions designed to help pharmacy leaders drive better business health, the wholesaler stated.

December 3, 2013

Officials in Rhode Island may set up a registry that would allow doctors and pharmacists to track patients who have problems with drug abuse, according to published reports.

NEW YORK — Officials in Rhode Island may set up a registry that would allow doctors and pharmacists to track patients who have problems with drug abuse, according to published reports.

The Associated Press reported that the proposed registry would track prescriptions for drugs that are controlled substance and allow healthcare professionals to track their usage, similar to a monitoring program set up in New York this year. A task force that includes state lawmakers, health officials and healthcare professionals met Monday to look at the idea.

December 3, 2013

The Food and Drug Administration has given tentative approval to a generic drug used to treat prostate disease, agency records showed.

SILVER SPRING, Md. — The Food and Drug Administration has given tentative approval to a generic drug used to treat prostate disease, agency records showed.

The FDA granted tentative approval to Roxane Labs' dutasteride capsules in the 0.5-mg strength. The drug is a generic version of GSK's Avodart, used to treat benign prostatic hyperplasia.

Tentative approval means that a drug meets the agency's conditions for approval, but can't receive final approval until Avodart loses its patent protection, which will occur in 2015.

 

December 2, 2013

The Food and Drug Administration has designated a drug made by Teva Pharmaceutical Industries as an orphan drug, the company said.

JERUSALEM — The Food and Drug Administration has designated a drug made by Teva Pharmaceutical Industries as an orphan drug, the company said.

Teva said the drug, Treanda (bendamustine hydrochloride), received the designation for indolent B-cell non-Hodgkins lymphoma through October 2015 that has progressed during or within six months of treatment with a regimen containing Rituxan (rituximab), marketed by Genentech and Biogen Idec. The FDA gives orphan drug designation to treatments for diseases affecting fewer than 200,000 people in the United States.

December 2, 2013

Sandoz will market an authorized generic version of an attention deficit hyperactivity disorder drug made by Shire under a contract between the two companies, Shire said Monday.

PHILADELPHIA — Sandoz will market an authorized generic version of an attention deficit hyperactivity disorder drug made by Shire under a contract between the two companies, Shire said Monday.

Shire said Sandoz, the generics division of Swiss drug maker Novartis, would market an authorized generic version of Adderall XR (amphetamine; dextroamphetamine).

November 26, 2013

German chemical and pharmaceutical giant Bayer plans to buy Norwegian drug maker Algeta for $2.4 billion, Algeta confirmed Tuesday.

OSLO, Norway — German chemical and pharmaceutical giant Bayer plans to buy Norwegian drug maker Algeta for $2.4 billion, Algeta confirmed Tuesday.

Responding to earlier media reports, the Norway-based maker of cancer drugs said Bayer would acquire it for 336 krone per share, equal to about $55.05. The company's share price increased to 349.40 krone, or $57.21 per share, in late-afternoon trading Tuesday on the Oslo Stock Exchange.

November 26, 2013

The Food and Drug Administration has accepted Purdue Pharma's regulatory approval application for a new opioid drug, Purdue said Tuesday.

STAMFORD, Conn. — The Food and Drug Administration has accepted Purdue Pharma's regulatory approval application for a new opioid drug, Purdue said Tuesday.

The drug maker announced the FDA's acceptance of its application for Targiniq (oxycodone hydrochloride; naloxone hydrochloride) controlled-release tablets. The drug combines oxycodone with the opioid agonist nalxone.

November 26, 2013

Generic drug maker Hospira will have its investor conference next week, the company said Tuesday.

LAKE FOREST, Ill. — Generic drug maker Hospira will have its investor conference next week, the company said Tuesday.

The drug maker, based in the Chicago area, will have the investor day at its headquarters on Dec. 5. Hospira specializes in manufacturing injectable generic drugs, including biosimilars for the European market.

The event will include slide presentations, and the company will stream it via audio webcast at its investors website, hospirainvestor.com.

 

November 25, 2013

The Food and Drug Administration has approved a new treatment made by Johnson & Johnson for hepatitis C, the drug maker said.

TITUSVILLE, N.J. — The Food and Drug Administration has approved a new treatment made by Johnson & Johnson for hepatitis C, the drug maker said.